Novel dual-targeting biologic shows potential in treatment-naive wet AMD

Sunir J. Garg, MD, FACS, FASRS, spoke about TH103, a novel biologic targeting both VEGF and heparan sulfate proteoglycans, in treatment-naive patients with wet age-related macular degeneration in this video interview.Results from the phase 1 single ascending dose study of TH103 (Kalaris Therapeutics) were presented at the American Society of Retina Specialists annual meeting.